20
total announcements
543980.BO · 15 min delayed
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced an earnings conference call for Q2 & H1 FY 27 to discuss operational and financial performance.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has scheduled a Board Meeting on October 23, 2026, to consider and approve Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming that the company's entire holding is in dematerialized form as of September 30, 2026, and no rematerialization requests were received during the quarter.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced the schedule of analyst/institutional investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The meetings will be held on September 28, 2026, and will discuss publicly available information.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced the transcript of its Q1 FY27 Earnings Conference Call, where the company discussed its financial results and provided updates on its operations, including the performance of its Dombivli Hospital and upcoming projects.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced the publication of its unaudited financial results for the quarter ended June 30, 2026, in compliance with SEBI regulations.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced the availability of the audio link of its analyst/investor conference call for Q1 FY27, which was held on August 3, 2026. The conference call was made available on the company's website.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has authorized its Chief Financial Officer, Mr. Harshad Purani, and Managing Director, Dr. Ankit Thakker, to determine materiality of events or information, and its Company Secretary, Ms. Suma Upparatti, to make disclosures to stock exchanges.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced its Q1FY27 results, with a total income of Rs 411.0 cr, EBITDA of Rs 78.4 cr, PBT of Rs 79.3 cr, and PAT of Rs 61.7 cr. The company's Dombivli hospital has completed its first full quarter of operations, with occupancy increasing steadily due to growing patient footfall and expansion of clinical services. The company has also initiated the process of insurance empanelment, which is expected to improve patient inflows in the coming quarters.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has acquired 100% of the equity share capital of Sulcus Private Limited for ₹3.78 crore, making Sulcus a wholly owned subsidiary of JHPPL and a step-down subsidiary of the Company.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd announced a change in management with the appointment of Mr. Harshad Purani as the Chief Financial Officer and Key Managerial Personnel, effective July 31, 2026. The company also approved its unaudited financial results for the quarter ended June 30, 2026, and disclosed the acquisition of 100% equity share capital of Sulcus Private Limited by its subsidiary, Jupiter Hospital Pharmacy Private Limited.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd announced its unaudited financial results for the quarter ended June 30, 2026, along with the appointment of a new CFO and the acquisition of a subsidiary. The company also disclosed the details of its related party transaction and the information will be available on its website.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd's board meeting on July 31, 2026, approved unaudited financial results for Q1 2026, appointed a new CFO, and acquired a subsidiary. The company also disclosed a limited review report and provided details as required by SEBI listing regulations.
Jupiter Life Line Hospitals Ltd
Catalyst Trusteeship Ltd has submitted a revised disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, correcting the percentage of pledged holding in Jupiter Life Line Hospitals Ltd to 5.11% from 30.67% due to the subdivision of equity shares from face value of ₹10 to ₹2 each.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the creation of a pledge over certain equity shares in favour of Catalyst Trusteeship Limited.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has announced an earnings conference call for Q1 FY 27, to be held on August 3, 2026, to discuss operational and financial performance.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has scheduled a Board Meeting on July 31, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26 to the stock exchanges. This report, which also forms part of the company's Annual Report for FY 2025-26, is a mandatory disclosure under Regulation 34(2)(f) of the SEBI Listing Regulations. The BRSR provides comprehensive details on the company's environmental, social, and governance (ESG) performance and includes general disclosures about its operations and employee demographics.
Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Ltd announced its 24th Annual General Meeting (AGM) to be held on July 17, 2026, via video conferencing. Key agendas include the adoption of financial statements for FY2025-26 and the re-appointment of Dr. Ajay Thakker as a director. The AGM will also seek approval for the re-designation and remuneration of Dr. Ajay Thakker from Chairman & Managing Director to Chairman & Whole Time Director for a period of five years. Most significantly, the company proposes a stock split, subdividing one equity share of face value ₹10 into five equity shares.